vTv Therapeutics Inc. (VTVT)
NASDAQ: VTVT · Real-Time Price · USD
16.40
-0.92 (-5.31%)
At close: Apr 1, 2025, 4:00 PM
17.50
+1.10 (6.70%)
After-hours: Apr 1, 2025, 4:18 PM EDT
vTv Therapeutics Employees
vTv Therapeutics had 16 employees as of December 31, 2023. The number of employees increased by 3 or 23.08% compared to the previous year.
Employees
16
Change (1Y)
3
Growth (1Y)
23.08%
Revenue / Employee
$63,562
Profits / Employee
-$1,153,875
Market Cap
52.31M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VTVT News
- 11 days ago - vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update - GlobeNewsWire
- 15 days ago - FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges - Benzinga
- 15 days ago - vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes - GlobeNewsWire
- 4 months ago - CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER - PRNewsWire
- 4 months ago - vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference - GlobeNewsWire
- 8 months ago - vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 8 months ago - vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold - GlobeNewsWire
- 10 months ago - vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes - GlobeNewsWire